Orgenesis Inc Revenue per Employee (ORGS), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket
 


Orgenesis Inc   (ORGS)
 

Orgenesis Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


With a revenue increase of 82.42% in the fourth quarter 2024, year on year to cumulative value of $1 million, Orgenesis Inc 's revenue per employee grew on a trailing twelve months basis to $ 7,089. The productivity of Orgenesis Inc 's employees was 0.0%, above the company average.
Within the Healthcare sector Employees of 537 other companies have achieved higher revenue per employee. While Orgenesis Inc 's total ranking has deteriorated compared to the previous quarter from 3420 to 3701. Orgenesis Inc has 146 employees.


What is Sales per Employee Ratio?







ORGS Revenue per Employee (Dec 31 2024)
IV. Quarter
(Sep 30 2024)
III. Quarter
(Jun 30 2024)
II. Quarter
(Mar 31 2024)
I. Quarter
(Dec 31 2023)
IV. Quarter
Y / Y Revenue Change 82.42 % 215.45 % 117.7 % -0.7 % -98.79 %
Sales per Employee (TTM) $ 7,089 6,158 4,534 3,623 3,630
ORGS's Total Ranking # 3701 # 3420 # 0 # 2227 # 0
Seq. Revenue Change -13.26 % 41.06 % 74.47 % -14.55 % 50 %


Revenue per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 202
Healthcare Sector # 538
Overall Market # 3701

Revenue per Employee Statistics
High Average Low
$ 246,747 $ 127,124 $ 4,240
(Dec 31 2022)   (Mar 31 2024)



Financial Statements
Orgenesis Inc 's Revenue MRQ $ 0 Millions Visit ORGS's Income Statement
Orgenesis Inc 's Revenues TTM $ 1 Millions Visit ORGS's aggregate revenue growth
What are ORGS's Sales? Visit ORGS's Sales by Segment




Other Ratios
Orgenesis Inc 's Income per Employee
Employees in Major Pharmaceutical Preparations
Major Pharmaceutical Preparations Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
ORGS's Revenue per Employee versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for ORGS's Competitors
Revenue per Employee for ORGS's Suppliers
Revenue per Employee for ORGS's Customers

You may also want to know
ORGS's Sales Growth Rates ORGS's Pe Price to earnings ratio ORGS's Receivables Turnover Ratio ORGS's Stock Quote
ORGS's Net Income Growth Rates ORGS's Ps Price to Sales ratio ORGS's Sales per Employee ORGS's Asset Turnover Ratio
ORGS's Net Margin ORGS's Pb Price to Book ratio ORGS's Financial Strength Ratios ORGS's Dividend Payout Ratio
Date modified: 2026-06-22T14:32:46+00:00




Companies with similar Revenue per Employee for 12 months ending Dec 31 2024, within Healthcare Sector Revenue per Employee Revenue 12 months ending Dec 31 2024Number of Employees Dec 31 2024
Oculis Holding Ag  11,433.33 $ 0.686  Million 60 
Purple Biotech Ltd  10,250.00 $ 0.041  Million
Skinvisible Inc   10,000.00 $ 0.020  Million
Scpharmaceuticals Inc   8,304.46 $ 36.332  Million 4,375 
Septerna Inc   8,269.23 $ 1.075  Million 130 
Aim Immunotech Inc   8,095.24 $ 0.170  Million 21 
Cg Oncology Inc   8,021.13 $ 1.139  Million 142 
Pluri Inc   7,369.57 $ 0.678  Million 92 
Hyperion Defi inc   6,370.67 $ 0.057  Million
Virax Biolabs Group Limited  6,016.12 $ 0.156  Million 26 
Applied Therapeutics Inc   5,687.50 $ 0.455  Million 80 
Aditxt Inc   5,152.15 $ 0.134  Million 26 
Clene Inc   4,329.11 $ 0.342  Million 79 
Aclarion Inc   4,156.73 $ 0.046  Million 11 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.